284 related articles for article (PubMed ID: 22244551)
1. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
Reynolds JV; Donohoe CL; McGillycuddy E; Ravi N; O'Toole D; O'Byrne K; Hollywood D
J Thorac Cardiovasc Surg; 2012 May; 143(5):1130-1137.e1. PubMed ID: 22244551
[TBL] [Abstract][Full Text] [Related]
2. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease.
Stiles BM; Mirza F; Coppolino A; Port JL; Lee PC; Paul S; Altorki NK
Ann Thorac Surg; 2011 Aug; 92(2):491-6; discussion 496-8. PubMed ID: 21704291
[TBL] [Abstract][Full Text] [Related]
3. Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases.
Lee PC; Port JL; Paul S; Stiles BM; Altorki NK
Ann Thorac Surg; 2009 Jul; 88(1):186-92; discussion 192-3. PubMed ID: 19559222
[TBL] [Abstract][Full Text] [Related]
4. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
5. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
6. Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years.
Internullo E; Moons J; Nafteux P; Coosemans W; Decker G; De Leyn P; Van Raemdonck D; Lerut T
Eur J Cardiothorac Surg; 2008 Jun; 33(6):1096-104. PubMed ID: 18407509
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
[TBL] [Abstract][Full Text] [Related]
8. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
9. Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus.
Stahl M; Lehmann N; Walz MK; Stuschke M; Wilke H
Eur J Cancer; 2012 Nov; 48(16):2977-82. PubMed ID: 22503151
[TBL] [Abstract][Full Text] [Related]
10. Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.
Tapias LF; Mathisen DJ; Wright CD; Wain JC; Gaissert HA; Muniappan A; Lanuti M; Donahue DM; Morse CR
Ann Thorac Surg; 2016 Mar; 101(3):1097-103. PubMed ID: 26652140
[TBL] [Abstract][Full Text] [Related]
11. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
12. Modern oncologic and operative outcomes for oesophageal cancer treated with curative intent.
Reynolds JV; McGillycuddy E; Ravi N; Donohoe C; O'Toole D; O'Byrne K; Hollywood D
Ir Med J; 2011 Sep; 104(8):235-8. PubMed ID: 22125876
[TBL] [Abstract][Full Text] [Related]
13. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
14. Outcome of low-volume surgery for esophageal cancer in a high-volume referral center.
Courrech Staal EF; van Coevorden F; Cats A; Aleman BM; van Velthuysen ML; Boot H; Peeters MJ; van Sandick JW
Ann Surg Oncol; 2009 Dec; 16(12):3219-26. PubMed ID: 19777184
[TBL] [Abstract][Full Text] [Related]
15. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy.
Law S; Kwong DL; Kwok KF; Wong KH; Chu KM; Sham JS; Wong J
Ann Surg; 2003 Sep; 238(3):339-47; discussion 347-8. PubMed ID: 14501500
[TBL] [Abstract][Full Text] [Related]
16. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer.
Vallböhmer D; Hölscher AH; DeMeester S; DeMeester T; Salo J; Peters J; Lerut T; Swisher SG; Schröder W; Bollschweiler E; Hofstetter W
Ann Surg; 2010 Nov; 252(5):744-9. PubMed ID: 21037429
[TBL] [Abstract][Full Text] [Related]
17. Patterns of lymph node metastasis and survival for upper esophageal squamous cell carcinoma.
Jang HJ; Lee HS; Kim MS; Lee JM; Zo JI
Ann Thorac Surg; 2011 Sep; 92(3):1091-7. PubMed ID: 21704967
[TBL] [Abstract][Full Text] [Related]
18. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
19. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G
Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
